Is Now The Right Time To Bet On Matinas BioPharma Holdings, Inc. (MTNB)?

Matinas BioPharma Holdings, Inc. (MTNB) shares saw a recent bid of $2.43 and 1.39M shares have exchanged hands in the recent trading session, yielding a -2.80% decline over the past week. The stock price increased 7.05% or $-0.16 versus $2.27 at the end of the prior session. This change led market cap to move at $233.35M, putting the price -39.10% below the 52-week high and 361.98% above the 52-week low. The company’s stock has a normal trading capacity of 434.58K shares while the relative volume is 3.19.

To stay one step ahead we extended our research by comparing different price targets. The stock notched a 12-month high of $7.00 while $8.00 target is by far the most aggressive out of analysts who are currently evaluating the company, $1 higher than the next highest 52-week price estimate. The lowest 12-month price target for the shares is $6.00, which would be an increase of about 147% of its current value. The mean target of $7.00 should be compared with the price when the stock was languishing around $0.53 a share. And it remains to be seen which target price MTNB can achieve without sacrificing much as the company is holding a 327.07% gain for the past twelve months.

By historical standards, Matinas BioPharma Holdings, Inc. remains a cheap stock. The company’s current price-earnings ratio amounts above the average P/E ratio of 222.31 times earnings. For now, Matinas BioPharma Holdings, Inc. is the toast of Wall Street as its ABR stands at 2.00 with 0 out of 2 analysts rating the stock a buy. Over the short term, some market observers may have noticed that Matinas BioPharma Holdings, Inc. has a 1.99% short float with 15 days to cover. It becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume. Matinas BioPharma Holdings, Inc. has far performed well this year, with the share price up 73.57% since January. Over the past 2 quarters, the stock is up 76.09%, compared with a fall of nearly -30.37% for 3 months and about -11.64% for the past 30 days.

Revenue for the quarter also killed consensus, coming in at $0M, compared to the consensus of 0M. Nonetheless, from here on out, earnings per share forecasts for the current quarter are $-0.05. The company is expected to report EPS as high as $-0.04 and as low as $-0.05 per share. Similarly, full-year EPS forecasts have ranged between $-0.38 and $-0.18. The mean EPS estimate is $-0.28. On the other side, sales forecasts for the current quarter are $0M. The stock is expected to report revenue as high as $0M and as low as $0M per share. Similarly, full-year sales forecasts have ranged between $0.01M and $0.01M. The mean revenue estimate is $0.01M.

Over the last 5 years, Analysts are expecting EPS growth rates to be at -17.20% this quarter and EPS estimate for next year reflect 14.30% growth rate.

Sell-side analysts also have something to say about this company.

Is Now The Right Time To Bet On Matinas BioPharma Holdings, Inc. (MTNB)? was last modified: June 14th, 2017 by Caleb Gerald
No Comments Yet

Leave a Reply

Your email address will not be published.

Stock News Magazine
Now there is no need to go through dozens of information portals, collecting a bit of the picture of the day. All the latest news from the region, the country, the world, you can find on the newsline of our site. The loudest incidents, interesting events, current opinions, people in the spotlight and much more – we gathered for you in one place.